Professor, Medicine, Medical College of GA at GRU
Oncology
Dr. Olivier Rixe, MD
|
|
Give Review
Olivier Rixe works in the field of Oncology. Olivier Rixe is a published doctor. He has 100 papers published. The most current publication "Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden." He accepts Medicare payments and is listed with Medicare.gov.
Publications
- P1.14A Dose Escalation Single Arm Phase Ib Combination Study of BEZ235 with Everolimus in Patients with Advanced Solid Malignancies.
- Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation.
- Phosphatidylserine-selective targeting and antiCancer effects of SapC-DOPS nanovesicles on brain tumors.
- Significant anti-tumor effect of bevacizumab in treatment of pineal Gland glioblastoma multiforme.
- Detection of EGFRvIII mutant DNA in the peripheral blood of Brain tumor patients.
- A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck Cancer.
- Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic Analysis.
- [Quantification of hepatic arterial and portal venous flow using ultrasound contrast agents for early detection of liver metastases of colorectal Cancers].
- [Acute alveolo-interstitial pneumopathies in HIV-negative patients treated with antineoplastic chemotherapy].
- Oxaliplatin plus vinorelbine in advanced non-small-cell lung Cancer: final results of a multicenter phase II study.
- Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic Breast carcinoma.
- Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotec...
- [Concomitant radiochemotherapy for non-small-cell lung Cancer: towards an ideal strategy].
- [Chemotherapy of non-small cell lung Cancer: non-cisplatin based combinations].
- A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
- Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced Cancer.
- [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of Cancer cells, interactions with ionizing radiation, specificity of carboplatin].
- Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter.
- Transactivation of the metallothionein promoter in cisplatin-resistant Cancer cells: a specific gene therapy strategy.
- A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.
- Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast Cancer.
- Endogenous interleukin 6 levels in patients with metastatic Malignant melanoma: correlation with tumor burden.
- Virus-free transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment induces tumor cell death.
- Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene.
- Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-Analysis?
- Initial management of primary mediastinal seminoma: radiotherapy or cisplatin-based chemotherapy?
- Lost potential in France?
- Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cel...
- [Telomeres, telomerase and Cancer].
- Docetaxel. A review of its role in breast Cancer treatment.
- A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung Cancer.
- Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced Ovarian carcinoma.
- Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours.
- Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced Ovarian carcinoma: preliminary results.
- CPT-11. The European experience.
- Liposomal deLivery of the herpes simplex virus thymidine kinase gene in glioma: improvement of cell sensitization to ganciclovir.
- [Resistance to antiCancer drugs].
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute''s Antic...
- In vitro sensitization of the B16 murine melanoma cells to ganciclovir by different RNA and plasmid DNA constructions encoding HSVtk.
- Gene transfer in hepatocarcinoma cell lines: in vitro optimization of a virus-free System.
- [Subclavicular skin metastasis of cervix Cancer].
- Direct gene transfer of a plasmid carrying the herpes simplex virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: in vivo study.
- Complete remission seven years after treatment for metastatic Malignant melanoma.
- Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced Malignant melanoma: a phase II study of 43 patients.
- [Adjuvant therapy of surgically removed stage I melanoma].
- Chemoimmunotherapy of metastatic Malignant melanoma. The Salpétrière Hospital (SOMPS) experience.
- Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.
- [Plasma tumor markers].
- Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic Malignant melanoma.
- [Breast Cancer: role of MRI in follow-up of cases treated].
- A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.
- Multicentre phase II study and pharmacokinetic Analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
- Epidermal growth factor receptor signaling in colorectal Cancer: preclinical data and therapeutic perspectives.
- Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving ...
- New challenges in kidney Cancer therapy: sunitinib.
- Hypertension as a predictive factor of Sunitinib activity.
- [Hormone-refractory prostate Cancer].
- Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: Analysis of its long-term prognostic value.
- [Neoadjuvant therapy for renal Cancer].
- Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal Cancer patients.
- [Skin signs associated with epidermal growth factor inhibitors].
- [Choroidal metastasis revealing pulmonary adenocarcinoma].
- [Regression of vena cava tumour thrombus in response to sorafenib].
- Breast Cancer screening in France: results of the EDIFICE survey.
- [Edifice program: analysis of screening exam practices for Cancer in France].
- Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib.
- [Primary carcinoma of the head of the epididymis].
- [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
- Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
- [Initial management in oncology: results of CPRIM surveys on 2,583 patient''s perceptions and expectations (outside AntiCancer Centers)].
- [New therapeutics strategies in renal cell carcinoma].
- Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.
- Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastat...
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors.
- Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity.
- A phase II study of the Cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunologica...
- Renal cell carcinoma: ten years of significant advances.
- Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for Ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
- Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
- Axitinib (AG-013736).
- Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
- Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of Cancer: current status and perspectives.
- Renal toxicity of targeted therapies.
- A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast Cancer.
- Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma.
- Validation of Analytic methods for biomarkers used in drug development.
- Scrotal cutaneous side effects of sunitinib.
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic Cancer: an open-label randomised phase II study.
- An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic Malignant melanoma patients.
- Cyclooxygenase-2 as a target for antiCancer drug development.
- Proteasome inhibition: a new approach for the treatment of malignancies.
- Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
- Incidence of renal insufficiency in Cancer patients and evaluation of information available on the use of antiCancer drugs in renally impaired patients.
- Impact of organised programs on colorectal Cancer screening.
- Is cell death a critical end point for antiCancer therapies or is cytostasis sufficient?
- Cancer screening in France: subjects'' and physicians'' attitudes.
- Axitinib treatment in patients with cytokine-refractory metastatic renal-cell Cancer: a phase II study.
- Macrocytosis due to treatment with sunitinib.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Drug Facts
| NPI NUMBER | 1255568721 | |
| NPPES Provider LastName | RIXE | |
| NPPES Provider FirstName | OLIVIER | |
| NPPES Provider ZIPCode | 309120004 | |
| NPPES Provider State | GA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 115.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255568721 |
| Last Name Of The Provider | RIXE |
| First Name Of The Provider | OLIVIER |
| View All |
Similar Doctors
|
|
Dr. Carlos H. Barcenas, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jigarkumar R. Parikh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard H. Bromer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth J. Manaloor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles L. Lutcher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas Samuel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ji Yuan, MB BS
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mitchell Z. Berger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mei B. Zheng, MD
This Doctor is OpenDoctor Recommended.
|